Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.

Cobenfy’s efficacy at treating the symptoms of patients with psychosis may vary between subgroups, according to a post-hoc ...

The phase 3 comeback story Bristol Myers Squibb investors were eagerly anticipating is not to be—at least not this year. | ...

Bristol Myers Squibb will enroll more patients in a key Phase 3 trial studying its drug Cobenfy in psychosis associated with ...

Analysts had noted "unease" from investors regarding the state of the Phase III ADEPT-2 trial, with BMS at one point telling Leerink Partners that the reopening of enrollment would be a "significant ...

Bristol Myers (BMY) will enroll additional patients in the ADEPT-2 study. Following a blinded review of the ADEPT-2 study ...

Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor ...

Shares of Bristol Myers Squibb BMY gained 5.62% after the company announced the continuation of the phase III ADEPT-2 study ...

Bristol Myers will enroll more patients in its Cobenfy Alzheimer's psychosis study after site irregularities, with FDA-supported analysis suggesting encouraging early signals.

Shares of drugmaker Bristol Myers Squibb were up almost 6% as of Wednesday afternoon, despite a delay in a late-stage study ...